TriangleDISEASE & TREATMENT SETTING
Tudriqev: unresectable advanced Melanoma
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
In combination with nivolumab for treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen
Broader topic: Melanoma
- Source population
- Not part of this definition
- Disease extent
- advanced
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- unresectable
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for Tudriqev (vusolimogene oderparepvec-wtpg) (accelerated-approval table). Only dimensions stated in that wording are part of this definition.
- source wording
- In combination with nivolumab for treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen
Study evidence for this setting
No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice